The identification of β-hydroxy carboxylic acids as selective MMP-12 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 19, 2009, Pages 5760-5763

  Holmes, Ian P ^a   Gaines, Simon ^a   Watson, Steve P ^a   Lorthioir, Olivier ^a   Walker, Adam ^a   Baddeley, Suzanne J ^a   Herbert, Shane ^a   Egan, Danielle ^a   Convery, Máire A ^a   Singh, Onkar M P ^a   Gross, Jeffrey W ^a   Strelow, John M ^a   Smith, Robert H ^a   Amour, Augustin J ^a   Brown, David ^a   Martin, Stephen L ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Angiogenesis; COPD; Inhibitor; Macrophage metalloelastase; Metalloproteinase; MMP 12; Rheumatoid arthritis

Indexed keywords

ASPARTIC PROTEINASE; BETA HYDROXY CARBOXYLIC ACID DERIVATIVE; COLLAGENASE 3; CYSTEINE PROTEINASE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; SERINE PROTEINASE; STROMELYSIN; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; IC 50; SUZUKI REACTION;

ANIMALS; BINDING SITES; CARBOXYLIC ACIDS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; GUINEA PIGS; HUMANS; MATRIX METALLOPROTEINASE 12; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 69949098313     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.155     Document Type: Article

References (14)

1. Skiles J.W., Gonnella N.C., and Jeng A.Y. Curr. Med. Chem. 8 (2001) 425
2. Matter H., and Schudok M. Curr. Opin. Drug Disc. Dev. 7 (2004) 513
3. Shapiro S.D. Curr. Opin. Cell Biol. 10 (1998) 602
4. Molet S., Belleguic C., Lena H., Germain N., Bertrand C.P., Shapiro S.D., Planquois J.-M., Delaval P., and Lagente V. Inflamm. Res. 54 (2005) 31
5. Demedts I.K., Brusselle G.G., Bracke K.R., Vermaelen K.Y., and Pauwels R.A. Curr. Opin. Pharmacol. 5 (2005) 257
6. Daheshia M. Curr. Med. Res. Opin. 21 (2005) 587
7. Anon, Expert Opin. Ther. Patents 2004, 14, 163.
8. Dublanchet A.-C., Ducrot P., Andrianjara C., O'Gara M., Morales R., Compère D., Denis A., Blais S., Cluzeau P., Courté K., Hamon J., Moreau F., Prunet M.-L., and Tertre A. Bioorg. Med. Chem. Lett. 15 (2005) 3787
9. Li W., Li J., Wu Y., Wu J., Hotchandani R., Cunningham K., McFayden I., Morgan P., Schlerman F., Xu X., Tam S., Goldman S.J., Williams C., Sypek J., and Mansour T.S. J. Med. Chem. 52 (2009) 1799
10. 50 values are given as the average of at least two replicates (n ≥ 2) with values deviating by less than two fold across the range. Assays were conducted using recombinant metalloproteinases from commercial sources, or generated in-house, with fluorescently tagged peptide substrates. Details available on request. (b) Protein for crystallization was obtained by overexpression of MMP12 residues 106-268 in E. coli followed by refolding and standard purification procedures in the presence of a hydroxamate tool compound. Crystals were grown with the tool compound from 100 mM Mes pH 5.2-5.6, 16-20% PEG 5KMME and 200 mM ammonium sulfate. The crystals are P1 with approximate cell dimensions of a = 46 Å, b = 65 Å, c = 68 Å, a = 66°, b = 84°, g = 71°. Complexes of 1, 6c and 7a were obtained by replacement soaking of the crystals. For all three complexes, data was collected at Daresbury synchrotron and density for the ligand was clear and unambiguous. Final Rfactors are 0.184, 0.172, 0.152 and Rfree 0.246, 0.217 and 0.219, respectively, with pdb deposition codes of 2wo8, 2wo9 and 2woa.
11. Massova I., Kotra L.P., Fridman R., and Mobashery S. FASEB J. 12 (1998) 1075
12. Terp G.E., Cruciani G., Christensen I.T., and Jørgensen F.S. J. Med. Chem. 45 (2002) 2675
13. Gaines, S.; Holmes, I. P.; Watson, S. P. WO 2004/110974.
14. Jackson R.W. Tetrahedron Lett. 42 (2001) 5163